Interferon alfa-2a
- Generic Name
- Interferon alfa-2a
- Drug Type
- Biotech
- CAS Number
- 76543-88-9
- Unique Ingredient Identifier
- 47RRR83SK7
- Background
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
- Indication
For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Chronic Myelogenous Leukemia (CML), Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Thrombocytosis
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000754
- Locations
- 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Ucsd, Avrc Crs, La Jolla, California, United States
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 52
- Registration Number
- NCT00000967
- Locations
- 🇵🇷
Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico
🇺🇸St. Jude/UTHSC CRS, Memphis, Tennessee, United States
🇵🇷San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
- Conditions
- HIV InfectionsAnus Neoplasms
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 98
- Registration Number
- NCT00000764
- Locations
- 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 48
- Registration Number
- NCT00000696
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.